首页> 美国卫生研究院文献>PLoS Computational Biology >Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment
【2h】

Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment

机译:F8基因和MHC-II变异中的多态性作为A型血友病治疗过程中抑制性抗因子VIII抗体发展的危险因素:计算评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The development of neutralizing anti-drug-antibodies to the Factor VIII protein-therapeutic is currently the most significant impediment to the effective management of hemophilia A. Common non-synonymous single nucleotide polymorphisms (ns-SNPs) in the F8 gene occur as six haplotypes in the human population (denoted H1 to H6) of which H3 and H4 have been associated with an increased risk of developing anti-drug antibodies. There is evidence that CD4+ T-cell response is essential for the development of anti-drug antibodies and such a response requires the presentation of the peptides by the MHC-class-II (MHC-II) molecules of the patient. We measured the binding and half-life of peptide-MHC-II complexes using synthetic peptides from regions of the Factor VIII protein where ns-SNPs occur and showed that these wild type peptides form stable complexes with six common MHC-II alleles, representing 46.5% of the North American population. Next, we compared the affinities computed by NetMHCIIpan, a neural network-based algorithm for MHC-II peptide binding prediction, to the experimentally measured values and concluded that these are in good agreement (area under the ROC-curve of 0.778 to 0.972 for the six MHC-II variants). Using a computational binding predictor, we were able to expand our analysis to (a) include all wild type peptides spanning each polymorphic position; and (b) consider more MHC-II variants, thus allowing for a better estimation of the risk for clinical manifestation of anti-drug antibodies in the entire population (or a specific sub-population). Analysis of these computational data confirmed that peptides which have the wild type sequence at positions where the polymorphisms associated with haplotypes H3, H4 and H5 occur bind MHC-II proteins significantly more than a negative control. Taken together, the experimental and computational results suggest that wild type peptides from polymorphic regions of FVIII constitute potential T-cell epitopes and thus could explain the increased incidence of anti-drug antibodies in hemophilia A patients with haplotypes H3 and H4.
机译:目前,对因子VIII蛋白治疗剂的中和性抗药抗体的开发是有效管理血友病A的最主要障碍。F8基因中常见的非同义单核苷酸多态性(ns-SNPs)以六种单倍型出现在人群中(H1至H6),其中H3和H4与开发抗药物抗体的风险增加有关。有证据表明,CD4 + T细胞应答对于开发抗药物抗体至关重要,并且这种应答需要患者的MHC-II类(MHC-II)分子呈递肽。我们使用合成因子ns-SNPs发生区域的因子VIII蛋白区域测量了肽-MHC-II复合物的结合和半衰期,结果表明这些野生型肽与六个常见的MHC-II等位基因形成了稳定的复合物,代表46.5占北美人口的百分比。接下来,我们将NetMHCIIpan(一种基于神经网络的MHC-II肽结合预测算法)的亲和力与实验测量值进行了比较,得出的结论是,这些值具有良好的一致性(ROC曲线下的面积为0.778至0.972,六个MHC-II变体)。使用计算结合预测因子,我们能够将分析扩展为(a)涵盖跨越每个多态性位置的所有野生型肽; (b)考虑更多的MHC-II变体,从而可以更好地估计整个人群(或特定亚群)中抗药物抗体临床表现的风险。对这些计算数据的分析证实,在与单倍型H3,H4和H5相关的多态性发生的位置处具有野生型序列的肽与阴性对照相比结合MHC-II蛋白的能力明显更高。总之,实验和计算结果表明,来自FVIII多态性区域的野生型肽构成了潜在的T细胞表位,因此可以解释单倍型H3和H4血友病A患者中抗药物抗体的发生率增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号